TABLE 3.
Comparison of baseline characteristics for hepatic responders a vs nonresponders
| Hepatic | ||
|---|---|---|
| Responders | Nonresponders | |
| Sex (M/F) | 11/13 | 8/4 |
| Age (y) | 56 (54‐67) | 60 (50‐65) |
| Transient elastography | ||
| CAP (dB/m) | 360 (338‐372) | 315 (281‐331)§ |
| LSM (kPa) | 5.9 (4.9‐7.4) | 8.3 (6.7‐11.6)§ |
| Anthropometry/body composition | ||
| Weight (kg) | 95 (84‐110) | 106 (98‐120) |
| BMI (kg/m2) | 33.2 (29.4‐37.0) | 34.8 (33.0‐40.5)* |
| Fat‐free mass (kg) | 58.3 (47.9‐65.5) | 69.6 (51.8‐75.5) |
| Fat mass (kg) | 37.6 (29.8‐46.2) | 48.2 (34.9‐54.5) |
| Total body water (L) | 44 (36‐48) | 51 (40‐55) |
| Visceral fat (L) | 4.1 (3,2‐6.8) | 6.2 (3,5‐9.2) |
| WC (cm) | 114 (105‐123) | 122 (112‐134) |
| Phase angle | 5.1 (4.6‐6.7) | 6.2 (4.6‐5.6) |
| Biochemistry | ||
| Liver function parameters | ||
| AST (U/L) | 21 (18‐27) | 28 (26‐40)* |
| ALT (U/L) | 27 (22‐32) | 42 (27‐72)* |
| γ‐GT (U/L) | 37 (24‐53) | 43 (29‐71) |
| AP (U/L) | 76 (62‐101) | 80 (69‐84) |
| Glucose‐related parameters | ||
| HbA1c (%) | 8.0 (7.3‐8.9) | 8.2 (7.2‐20.0) |
| FPG (mg/dL) | 169 (140‐200) | 188 (141‐230) |
| Insulin (mIU/mL) | 12.0 (10.0‐23.6) | 15.3 (11.9‐17.5) |
| C‐Peptide (ng/mL) | 2.3 (1.5‐3.1) | 2.5 (1.9‐3.8) |
| HOMA‐IR score (FPGXIns/405) | 5.8 (3.8‐10.6) | 7.8 (3.8‐10.9) |
| Lipid status | ||
| TC (mg/dL) | 179 (144‐209) | 171 (156‐202) |
| LDL‐C (mg/dL) | 104 (77‐122) | 94 (88‐121) |
| HDL‐C (mg/dL) | 44 (38‐49) | 45 (37‐52) |
| TG (mg/dL) | 152 (124‐238) | 165 (96‐258) |
P value between the two groups determined with the Mann‐Whitney U test: *P ≤ .05, $ P ≤ .01.
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assessment measuring insulin resistance; LDL, low‐density lipoprotein; LSM, liver stiffness measurement; TC, total cholesterol; TG, triglyceride; WC, waist circumference; γ‐GT, gamma‐glutamyl transpeptidase.
Hepatic responders were defined as those having a lower CAP value at the final follow‐up as compared to baseline (CAP values were available for N = 36 patients at 6 mo).